05/19/2015

Symposium on "Targeting tumor angiogenesis with antibody-based technologies", Centro Nacional de Biotecnología, Madrid (Spain). Date: June 8th, 2015.

Registration deadline: May 31st 2015.

More information http://angiobodies.com/congreso2015.asp...

04/07/2015

Symposium on "Targeting tumor angiogenesis with antibody-based technologies", Centro Nacional de Biotecnología, Madrid (Spain). Date: June 8th, 2015.

In this event, which will be held in Madrid this coming June, experts from International research institutes will review the current concept of targeting tumor blood vessels, the potential of antibody-based therapies, and will try to identify future challenges in the field through an interdisciplinary approach.

More information http://angiobodies.com/congreso2015.asp...

10/10/2013

An engineered bacteria to deliver antibodies into human cells

Scientists at the National Center for Biotechnology (CNB) have patented non-invasive Escherichia coli bacteria carrying functional molecular syringes assembled by a Type III protein secretion system (T3SS) that are able to secrete and translocate to the cytoplasm of human cells single domain antibodies (sdAb) fragments with full capacity to bind to their cognate antigens.

The proof of concept developed by Dr Luis Ángel Fernández has been done with intestinal pathogenic E. coli strains that use a T3SS to inject specific bacterial proteins referred to as “effectors”, into mammalian cells.

Nanobodies appeared specially suited for this application given their potential as enzyme inhibitors, monomeric nature, stability and size (2-3 nm) that fit in the protein channels of bacteria syringes.

Currently, industrial partners interested in a patent license are being sought.

More information http://www.cnb.csic.es/index.php/es/info...

02/11/2013

First Annual Scientific Meeting 'Angiobodies 2.0'

1ª reunión científica de los grupos integrantes de la red 'angiobodies 2.0' junto con los asesores externos para discutir los resultados y trazar las líneas de desarrollo futuras.

More information http://www.angiobodies.com...

05/10/2012

A new target for antiangiogenic and antitumor therapies.

Científicos del Centro Nacional de Investigaciones Oncológicas (CNIO) han demostrado la utilidad de La proteína ephrinB2, implicada en angiogenésis y linfoangiogénesis, como diana para el desarrollo de terapias antiangiogénicas y antitumorales, basadas en el bloqueo de la citada proteína. Este trabajo está enmarcado dentro de la red 'Angiobodies' financiada por la Comunidad de Madrid y en la que han paraticipado 2 grupos de dicha red, CNIO y UAM.

More information http://www.europapress.es/salud/noticia-...